GlaxoSmithKline plc's (LON: GSK) majority-owned ViiV Healthcare has seen positive results from two Phase III studies investigating its two-drug HIV treatment, Proactive Investors reported on Thursday.
The current standard treatment involves a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors.
However, results from the GEMINI-1 and GEMINI-2 studies show a two-drug regimen of dolutegravir and lamivudine is just as effective.
The studies were designed to evaluate the safety and efficacy of the two-drug regimen compared to the standard three-drug regimen. Both GEMINI-1 and GEMINI-2 met their primary endpoint for non-inferiority, a standard measure of HIV control, at Week 48.
ViiV plans to submit for regulatory approval for the two-drug regimen later this year. Full results from the studies will be presented at an upcoming meeting.
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention